Enhanced Nanovectors for Targeted Active Substance Delivery

This inventive concept discloses a series of direct improvements and enhancements to nanovectors for delivering active substances in the body, addressing limitations of existing nanovectors by incorporating targeting moieties, pH-sensitive coatings, built-in imaging agents, cell-penetrating peptides, and hydrophilic polymer coatings to increase tissue specificity, controlled release, and biocompatibility.

The original patent, 'Nanovectors and uses', describes nanovectors comprising polysiloxane-based nanoparticles for delivering active substances in the body. However, these nanovectors may lack tissue specificity, have uncontrolled release profiles, and exhibit limited biocompatibility. The new inventive concept addresses these limitations by introducing targeted, controlled, and biocompatible nanovectors.

The new inventive concept comprises a system for delivering active substances, where polysiloxane-based nanoparticles with mean diameters of less than 10 nm are modified to include targeting moieties for enhanced tissue specificity. Additionally, the nanoparticles can be functionalized with pH-sensitive coatings for controlled release of the active substance, built-in imaging agents for real-time tracking, and conjugated to cell-penetrating peptides for enhanced cellular uptake. Furthermore, the nanoparticles can be synthesized with a hydrophilic polymer coating for improved biocompatibility.

The new claims introduce novel features that distinguish them from the original patent, including targeting moieties, pH-sensitive coatings, built-in imaging agents, cell-penetrating peptides, and hydrophilic polymer coatings. These features provide a non-obvious solution to the limitations of existing nanovectors, demonstrating a significant inventive step.

Alternative embodiments of the inventive concept may include using different types of nanoparticles, varying the targeting moieties, or incorporating additional features such as stimuli-responsive coatings or enzymatic triggers. These variations ensure broad conceptual coverage and adaptability to diverse therapeutic applications.

The enhanced nanovectors have significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the development of targeted therapies for cancer, neurodegenerative diseases, and other conditions. The market for nanovector-based drug delivery systems is expected to grow substantially, driven by the need for more efficient and effective treatments.